Alto Neuroscience, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Company gets cash to expand depression drug trials, showing investors it's growing the business.
Official document details how company is raising money and where it will spend it.
Shows company has significant runway to fund drug development without running out of money soon.
Director with Bristol Myers Squibb and startup experience brings expertise to guide drug development.
Allows employees to buy company stock, aligning their interests with long-term company success.
Quarterly earnings show whether company is spending money wisely on drug development.
Quarterly earnings show whether company is spending money wisely on drug development.
Stocky reads Alto Neuroscience, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Alto Neuroscience, Inc.'s most recent tracked filing was a 8-K on 14 Jul 2026: Raises $93.9 million selling 3.78 million shares at $26.48.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.